Teens Travel to Washington, D.C., to Speak Out for Cystic Fibrosis
Originally posted in Cystic Fibrosis Foundation
Originally posted in Cystic Fibrosis Foundation
Jun
24
2011
24
2011
Jun
24
2011
24
2011
Jun
20
2011
20
2011
Scientists Develop First Ever Drug To Treat ‘Celtic Gene’ In Cystic Fibrosis Sufferers, UK
Originally posted in Cystic Fibrosis News From Medical News Today
An international research team led by Queen’s University have developed a ground breaking treatment for Cystic Fibrosis sufferers. The new drug will benefit sufferers who have the ‘Celtic Gene’, a genetic mutation which is particularly common in Ireland…
Jun
19
2011
19
2011
Scientists Develop First Ever Drug To Treat ‘Celtic Gene’ In Cystic Fibrosis Sufferers
Originally posted in Cystic Fibrosis News From Medical News Today
An international research team led by Queen’s University have developed a ground breaking treatment for Cystic Fibrosis sufferers. The new drug will benefit sufferers who have the ‘Celtic Gene’, a genetic mutation which is particularly common in Ireland…
Jun
17
2011
17
2011
Jun
17
2011
17
2011
Jun
17
2011
17
2011
Aradigm Reports Successful ORBIT-1 Bronchiectasis Study With Inhaled Liposomal Ciprofloxacin
Originally posted in Cystic Fibrosis News From Medical News Today
Aradigm Corporation (OTCBB:ARDM) (the “Company”) today announced positive top line data from its recently concluded Phase 2b study (Once-Daily Respiratory Bronchiectasis Inhalation Treatment – ORBIT-1) with Aradigm’s ciprofloxacin for inhalation (CFI, ARD-3100, LipoquinTM) in patients with non-cystic fibrosis bronchiectasis (BE)…
Jun
16
2011
16
2011
Jun
16
2011
16
2011
Jun
16
2011
16
2011
Lamellar Biomedical Secures Its First Orphan Drug Licence
Originally posted in Cystic Fibrosis News From Medical News Today
Glasgow biopharmaceutical firm, Lamellar Biomedical Ltd, launched four years ago to develop a new class of therapies for the prevention, treatment and control of severe respiratory disease, today announced that their lead clinical candidate LMS-611 for the treatment of patients with cystic fibrosis has received Orphan Drug Designation from the European Commission…
Jun
16
2011
16
2011
Altering Messenger RNA Holds Promise For Treating Cystic Fibrosis, Muscular Dystrophy, Cancer
Originally posted in Cystic Fibrosis News From Medical News Today
In a new study published in the journal Nature, scientists discovered an entirely new way to change the genetic code. The findings, though early, are significant because they may ultimately help researchers alter the course of devastating genetic disorders, such as cystic fibrosis, muscular dystrophy and many forms of cancer…
Jun
16
2011
16
2011
Abbott Receives FDA Approval For CREON
Originally posted in Cystic Fibrosis News From Medical News Today
Abbott (NYSE: ABT) announced that the U.S. Food and Drug Administration (FDA) has approved an infant-specific dose of CREON
Jun
14
2011
14
2011
Jun
14
2011
14
2011
Jun
11
2011
11
2011
Vertex Plans To Provide Access To Potential CF Therapy VX-770 For Patients With Critical Medical Need
Originally posted in Cystic Fibrosis News From Medical News Today
Vertex Pharmaceuticals Inc. announced a plan to provide VX-770, a CF medicine in development, to people with the G551D mutation who are in critical medical need and may benefit from treatment prior to potential approval of the drug from the U.S. Food and Drug Administration (FDA)…
Jun
11
2011
11
2011
Insmed’s ARIKACE
Originally posted in Cystic Fibrosis News From Medical News Today
Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, announced positive data through six treatment cycles (72 weeks total duration) of its Phase 2 clinical trial program for ARIKACE
Jun
10
2011
10
2011
Phase 3 STRIVE Study Of VX-770 Showed Durable Improvements In Lung Function And Other Measures Of Disease Among People With A Specific Type Of CF
Originally posted in Cystic Fibrosis News From Medical News Today
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the final results from its pivotal Phase 3 STRIVE study that evaluated VX-770, a medicine in development that targets the defective protein that causes cystic fibrosis (CF). STRIVE was designed to evaluate VX-770 among 161 people 12 years or older with a mutation known as G551D in the CF gene…
Jun
10
2011
10
2011
Jun
10
2011
10
2011
Jun
10
2011
10
2011
Jun
10
2011
10
2011
Jun
10
2011
10
2011
Mutations In Essential Genes Often Cause Rare Diseases
Originally posted in Cystic Fibrosis News From Medical News Today
Mutations in genes essential to survival are behind so-called orphan diseases, explaining in part why these diseases are rare and often deadly, according to a study appearing in The American Journal of Human Genetics…
Jun
10
2011
10
2011
Phase 2 Study Of Two Potential CF Therapies – VX-770 And VX-809 – Shows Promising Results In Patients With Most Common Mutation
Originally posted in Cystic Fibrosis News From Medical News Today
Vertex Pharmaceuticals Incorporated and the Cystic Fibrosis Foundation today announced promising results from an ongoing Phase 2 study evaluating combinations of VX-770 and VX-809, potential medicines designed to treat the defective protein that causes cystic fibrosis. The study enrolled 62 people with two copies of the most common CF mutation, known as Delta F508. The trial lasted three weeks…
Jun
09
2011
09
2011
Jun
09
2011
09
2011
Jun
07
2011
07
2011
Aradigm Receives FDA Orphan Drug Designation For Ciprofloxacin For Inhalation In Bronchiectasis
Originally posted in Cystic Fibrosis News From Medical News Today
Aradigm Corporation (OTCBB:ARDM) (the “Company”) today announced it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for ciprofloxacin for inhalation for the management of bronchiectasis (BE)…
Jun
02
2011
02
2011
Jun
02
2011
02
2011
by Raelene
